Welcome to our dedicated page for TAO Synergies SEC filings (Ticker: TAOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TAO Synergies Inc. (Nasdaq: TAOX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as it pursues a TAO-focused digital asset treasury strategy. As a Nasdaq-listed emerging growth company, TAO Synergies files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements on Schedule 14A, all of which give detail on its cryptocurrency and decentralized AI activities.
In its Form 8-K filings, TAO Synergies has reported material events such as private placements of Series E convertible preferred stock and warrants, use of proceeds for general corporate purposes and working capital, and changes in board composition and advisory relationships. These filings describe terms of preferred stock, dividend rights, conversion prices, warrant exercise prices, and related registration rights agreements, which are important for understanding potential dilution and capital structure as the company finances its TAO treasury strategy.
The company’s proxy materials, including a definitive proxy statement on Schedule 14A, outline proposals for stockholder approval, such as authorizing share issuances under Nasdaq Listing Rule 5635(d), amending the TAO Synergies Inc. 2020 Equity Incentive Plan, and ratifying its independent registered public accounting firm. Special meeting results reported on Form 8-K show how stockholders have voted on equity incentive plan amendments and share issuance authorizations linked to prior financings.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, voting outcomes, and structural changes without requiring investors to read every page. Users can quickly see how TAO Synergies structures its preferred stock and warrants, how equity incentive plans evolve, and how governance decisions align with its digital asset treasury focus. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and proxy statements are available as they are filed, helping investors track regulatory developments around the TAOX ticker.
TAO Synergies Inc. reported that Executive Chairman Joshua Silverman received a grant of stock options. He was awarded 200,000 options to buy common stock at an exercise price of $4.8000 per share, expiring on May 18, 2036.
All of these options will vest and become immediately exercisable after he completes one year of service following May 18, 2026, according to the filing footnote. Following this grant, he holds 200,000 stock options directly.
TAO Synergies Inc. director Bruce Bernstein received a grant of stock options to acquire 55,000 shares of common stock. The options have an exercise price of $4.80 per share and expire on May 18, 2036. All of the options vest and become exercisable after the completion of one year of service following May 18, 2026, leaving Bernstein with 55,000 stock options reported as directly owned after this grant.
TAO Synergies Inc. director William S. Singer received a grant of stock options for 35,000 shares of common stock. The options have an exercise price of $4.80 per share and expire on May 18, 2036. All options vest after one year of service following May 18, 2026.
TAO Synergies Inc. Chief Financial Officer Robert Weinstein received a grant of stock options to acquire 30,000 shares of common stock at an exercise price of $4.80 per share. According to the grant, all options vest after the completion of one year of service following May 18, 2026 and expire on May 18, 2036, leaving him with 30,000 options outstanding from this award.
TAO Synergies Inc. director Robert Ephron received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $4.80 per share and expire on May 18, 2036. Following this grant, he holds 10,000 stock options directly. According to the terms, all of these options vest and become exercisable after he completes one year of service following May 18, 2026.
TAO Synergies Inc. reported a sharp swing to profitability for the quarter ended March 31, 2026, driven by gains on its cryptocurrency holdings. The company generated $388,774 in revenue from TAO staking while posting an operating loss of $1.3 million, mainly from $1.7 million of general and administrative costs and modest research and development spending.
Net income reached $4.25 million, up from $0.39 million a year earlier, largely due to a $6.84 million unrealized gain on digital assets and $0.35 million of gains on Yuma partnership investments, partially offset by a $1.65 million loss from changes in derivative liabilities. Cash and cash equivalents were $3.6 million and digital assets were $25.2 million, giving total assets of $31.0 million.
The company has adopted a concentrated, long-only cryptocurrency treasury strategy focused on TAO, with about 87.3% of treasury holdings in TAO as of March 31, 2026 and 82,210 tokens held. Management believes current cash and TAO market value can fund operations for at least 12 months while it continues accumulating TAO and evaluates paths forward for its Bryostatin-1 drug program, but it also acknowledges that additional capital will be needed to support its crypto treasury strategy.
TAO Synergies Inc. director William S. Singer received a grant of stock options giving him the right to buy 800 shares of common stock. The options have an exercise price of $5.52 per share and were granted at no cost.
All of these options vest and become exercisable upon completion of one year of service following April 7, 2026, and they expire on April 7, 2036. After this grant, Singer directly holds 800 stock options linked to TAO Synergies common shares.
TAO Synergies Inc. director Ephron Robert received a stock option grant for 800 shares of common stock. The option has an exercise price of $5.52 per share and expires on April 7, 2036. According to the disclosure, all 800 options will vest after the holder completes one year of service following April 7, 2026.
TAO Synergies Inc. director Bruce Bernstein received a grant of stock options covering 800 shares of common stock at an exercise price of $5.52 per share. These options were awarded at no cost and will fully vest after he completes one year of service following April 7, 2026.
TAO Synergies Inc. (formerly Synaptogenix) is transitioning from a pure biopharmaceutical focus on its bryostatin-1 Alzheimer’s program to a differentiated cryptocurrency treasury strategy centered on TAO, the native token of the Bittensor decentralized AI network.
The company now seeks to allocate roughly 75–100% of its “excess cash” into TAO, staking tokens via providers such as tao5 and Yuma to pursue yield and potential capital appreciation. As of September 10, 2025, about 88% of treasury holdings were in TAO, with all tokens staked. TAO Synergies uses BitGo as custodian and BitGo Prime as trading intermediary and is exploring, but has not yet implemented, hedging. The business also launched a media platform, The TAO Daily, and engaged crypto-focused consultants James Altucher and Joseph Jacks, granting them multi-year warrants as equity incentives. Legacy bryostatin-1 clinical programs in Alzheimer’s disease and other neurodegenerative indications continue under existing academic and licensing collaborations, though prior Phase 2 trials have not met primary endpoints.